news
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity…
23 September 2021 | By Anna Begley (Drug Target Review)
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.